Showing results (1071-1080 of 1,174) with videos related to

Sort By:
Pageof 118
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2020
Modeling the Impact of Cardiopulmonary Irradiation on Overall Survival in NRG Oncology Trial RTOG 0617Maria Thor, Joseph O Deasy, Chen Hu, et al.
European Journal of Medicinal Chemistry|October 15, 2018
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemiaXuesong Liu, Beilei Wang, Cheng Chen, et al.
JAMA Oncology|June 27, 2024
Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical TrialStephen G Chun, Chen Hu, Ritsuko U Komaki, et al.
Oncotarget|April 14, 2016
Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AMLAoli Wang, Hong Wu, Cheng Chen, et al.
Annals of Surgical Oncology|February 7, 2022
Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative ToxicityColin S Hill, Lauren M Rosati, Chen Hu, et al.
Journal of Medicinal Chemistry|August 23, 2016
Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT KinaseBinhua Li, Aoli Wang, Juan Liu, et al.
The Lancet. Oncology|January 21, 2015
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 studyJeffrey D Bradley, Rebecca Paulus, Ritsuko Komaki, et al.
JAMA Oncology|November 26, 2015
Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical TrialBenjamin Movsas, Chen Hu, Jeffrey Sloan, et al.
Oncotarget|September 15, 2016
Ibrutinib targets mutant-EGFR kinase with a distinct binding conformationAoli Wang, Xiao-E Yan, Hong Wu, et al.
Physiologia Plantarum|April 25, 2024
ChloroSpec: A new in vivo chlorophyll fluorescence spectrometer for simultaneous wavelength- and time-resolved detectionSanchali Nanda, Tatyana Shutova, Maximiliano Cainzos, et al.
Pageof 118